Dynavax Technologies' data thus far in squamous cell carcinoma of the head and neck and melanoma are "compelling" and will see SD-101 "finally getting into" the stock as the Street comes to appreciate the oncology side of the business, William Blair analyst Y. Katherine Xu tells investors in a research note. She points out that SD-101, or Dynavax's other oncology assets, are not included in her $40 fair value estimate of the stock. These opportunities represent "significant upside to our valuation," Xu contends. The analyst keeps an Outperform rating on Dynavax. The stock closed yesterday at $18.85.